Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.
1. Twenty-two maturity-onset type diabetics treated with oral hypoglycaemic agents entered a single-blind crossover study using placebo (periods A and C, 2 months each) and clofibrate (2 g/day; period B; 2 months). 2. In thirteen patients, under reasonably good control, clofibrate did not reduce fasting or post-prandial blood glucose, nor 24 h glycosuria; no improvement was noted in the M-value, an index of diabetes control. 3. In contrast, in nine patients, with poor diabetes control, clofibrate reduced 24 h glycosuria and significantly improved the M-value. 4. In all patients, clofibrate therapy was associated with a significant 19-23% reduction in plasma fibrinogen. 5. It is suggested that addition of clofibrate may be useful in maturity-onset diabetics not adequately controlled by diet combined with oral hypoglycaemic agents.
D001786:Blood Glucose / Q000378:metabolism; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000009:adverse effects / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000188:drug therapy*; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006029:Glycosuria / Q000517:prevention & control; D006801:Humans; D007004:Hypoglycemic Agents / Q000378:metabolism / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D010919:Placebos
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D008055:Lipids; D010919:Placebos; D005340:Fibrinogen; D002994:Clofibrate